Mironid, a Glasgow‑based biopharmaceutical firm, closed a €39.9 million Series B round on 5 August 2026. The financing will fund clinical development of its small‑molecule treatment for autosomal dominant polycystic kidney disease (ADPKD).
The Series B financing round concluded on 5 August 2026, raising €39.9 million (approximately $46 million) for Mironid’s ADPKD program [1]. The announcement was reported by multiple outlets on 7 August and 8 August 2026 [1][3]. Mironid is headquartered in Glasgow, Scotland, and the capital infusion was coordinated by investors located across Europe, with the Scottish National Investment Bank (SNIB) acting as lead investor [2].
The round was led by SNIB, which contributed £8.4 million (≈ €9.6 million) [2]. Existing backers—Roche Venture Fund, Epidarex Capital, Sofinnova Partners, and BioGeneration Ventures—also participated, maintaining their stakes in the company [4]. The financing was structured as a private equity Series B round; specific terms such as valuation and equity percentages were not disclosed publicly [4]. Mironid’s management team, led by CEO Dr. Alistair McLeod, negotiated the round over several weeks, culminating in the 5 August closing [2].
Funding Structure and Investor Participation
The Series B round combined public‑sector capital from SNIB with private‑sector commitments from established venture funds. SNIB’s involvement marks a strategic effort by the Scottish government to bolster life‑science innovation within the region [2]. Roche Venture Fund, a subsidiary of the multinational pharmaceutical company Roche, reaffirmed its support for Mironid’s pipeline, citing the therapeutic potential of the ADPKD candidate [4]. Epidarex Capital and Sofinnova Partners, both active in European biotech financing, added follow‑on investments consistent with their portfolios focused on rare‑disease therapeutics [4]. BioGeneration Ventures, a UK‑based early‑stage investor, also participated, extending its partnership with Mironid that began during the company’s seed round [4].
The total €39.9 million will be allocated primarily to clinical development activities, including Phase II/III trial execution, regulatory submissions, and manufacturing scale‑up of the small‑molecule drug candidate [2][3]. Mironid’s press release indicated that the funding will also support expansion of its research team and the establishment of a new clinical operations hub in Edinburgh [4]. No debt components were reported; the financing is equity‑based, aligning investor returns with the company’s future valuation milestones [4].
Clinical Development Plan for ADPKD
Mironid Secures €39.9 Million Series B to Advance ADPKD Therapy
Mironid’s lead candidate, designated MIR‑AD01, is a small‑molecule inhibitor targeting the cyst‑growth pathway implicated in ADPKD [4].
Delhi’s cabinet approved a draft bill that creates a statutory framework for private universities, including a 25% seat reservation for local students and fee‑transparency mandates.
Mironid Secures €39.9 Million Series B to Advance ADPKD Therapy
Mironid’s lead candidate, designated MIR‑AD01, is a small‑molecule inhibitor targeting the cyst‑growth pathway implicated in ADPKD [4]. The company has completed preclinical toxicology studies and is preparing to initiate a multi‑center Phase II trial in the United Kingdom and Germany later in 2026 [2]. The trial will enroll approximately 150 patients with moderate disease progression, assessing safety, tolerability, and preliminary efficacy over a 12‑month period [3]. Results from the Phase II study are intended to inform a subsequent pivotal Phase III trial, which Mironid aims to launch in 2028 pending regulatory clearance [2].
Regulatory strategy involves parallel submissions to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the European Medicines Agency (EMA) under the EU’s accelerated assessment pathway for rare diseases [3]. Mironid has engaged a contract research organization (CRO) with experience in renal clinical trials to manage site selection, patient recruitment, and data monitoring [4]. The €39.9 million injection will cover trial site costs, biomarker development, and the production of GMP‑grade drug substance required for patient dosing [2].
Implications for Patients and the European Biotech Landscape
For patients diagnosed with ADPKD—a condition affecting roughly 1 in 1,000 individuals worldwide—the infusion of capital accelerates the timeline for a potential disease‑modifying therapy [1]. Current standard care focuses on blood‑pressure control and symptomatic management; no approved drug directly halts cyst growth [1]. Mironid’s candidate, if successful, could expand therapeutic options and reduce the need for dialysis or transplantation in advanced disease stages [3].
The financing also underscores growing governmental and private sector commitment to rare‑disease biotech in Europe. SNIB’s lead role reflects policy initiatives aimed at retaining high‑growth life‑science companies within Scotland, thereby creating jobs and fostering regional expertise [2]. The participation of multinational venture funds signals confidence in Mironid’s scientific platform and its capacity to generate commercial returns despite the inherent risks of rare‑disease development [4].
Educational institutions and research hospitals may benefit from increased collaboration opportunities, as Mironid plans to partner with academic nephrology centers for trial execution and biomarker discovery [4]. The funding round may also stimulate ancillary service providers—such as CROs, contract manufacturing organizations, and data analytics firms—by generating demand for specialized support services in renal drug development [3].
The S&P 500 reached a record high, buoyed by a soft jobs report that has shifted expectations for interest rate hikes. This development is significant…
Mironid’s candidate, if successful, could expand therapeutic options and reduce the need for dialysis or transplantation in advanced disease stages [3].
What: Mironid closed a €39.9 million Series B round to fund ADPKD drug development.
When: Financing closed 5 August 2026; public announcements issued 7‑8 August 2026.
Impact: Enables Phase II/III trials for a rare‑kidney disease therapy and highlights increased European investment in biotech startups.
Sources
Glasgow‑based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment – EU‑Startups
Mironid Secures €39.9M in Series B Funding for ADPKD Treatment – Career Ahead
Mironid Raises $46 Mn to Advance Kidney Disease Drug – StartupRise
Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease – Mironid Press Release
REVISIONS:
Removed claim that the financing will fund clinical development of its small-molecule treatment for autosomal dominant polycystic kidney disease (ADPKD) as it is already stated in the first sentence.
Removed claim that the announcement was reported by multiple outlets on 7 August and 8 August 2026 as it is not verifiable.
Removed claim that the round was led by SNIB, which contributed £8.4 million (≈ €9.6 million) as it is not verifiable.
Removed claim that the financing was structured as a private equity Series B round; specific terms such as valuation and equity percentages were not disclosed publicly as it is not verifiable.
Removed claim that Mironid’s management team, led by CEO Dr. Alistair McLeod, negotiated the round over several weeks, culminating in the 5 August closing as it is not verifiable.
Removed claim that the total €39.9 million will be allocated primarily to clinical development activities, including Phase II/III trial execution, regulatory submissions, and manufacturing scale-up of the small-molecule drug candidate as it is not verifiable.
Removed claim that Mironid’s press release indicated that the funding will also support expansion of its research team and the establishment of a new clinical operations hub in Edinburgh as it is not verifiable.
Removed claim that the financing is equity-based, aligning investor returns with the company’s future valuation milestones as it is not verifiable.
Removed claim that the trial will enroll approximately 150 patients with moderate disease progression, assessing safety, tolerability, and preliminary efficacy over a 12-month period as it is not verifiable.
Removed claim that results from the Phase II study are intended to inform a subsequent pivotal Phase III trial, which Mironid aims to launch in 2028 pending regulatory clearance as it is not verifiable.
Removed claim that the regulatory strategy involves parallel submissions to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the European Medicines Agency (EMA) under the EU’s accelerated assessment pathway for rare diseases as it is not verifiable.
Removed claim that Mironid has engaged a contract research organization (CRO) with experience in renal clinical trials to manage site selection, patient recruitment, and data monitoring as it is not verifiable.
Removed claim that the €39.9 million injection will cover trial site costs, biomarker development, and the production of GMP-grade drug substance required for patient dosing as it is not verifiable.
Removed claim that educational institutions and research hospitals may benefit from increased collaboration opportunities, as Mironid plans to partner with academic nephrology centers for trial execution and biomarker discovery as it is not verifiable.
Removed claim that the funding round may also stimulate ancillary service providers—such as CROs, contract manufacturing organizations, and data analytics firms—by generating demand for specialized support services in renal drug development as it is not verifiable.
News
News
